课题基金 / 基金详情

USE OF FAS LIGAND TO SUPPRESS ARTHRITIS

USE OF FAS LIGAND TO SUPPRESS ARTHRITIS
使用 FAS 配体抑制关节炎
批准号:
6294448
负责人:
DONALD BELLGRAU
金额:
$10.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2001
资助国家:
美国
项目状态:
已结题
起止时间:
2001-07-01 至 2001-12-31

项目摘要

项目成果

DONALD BELLGRAU的其他基金

相关文献

中文摘要
翻译
几个小组的初步报告已经证明了
英文摘要
DESCRIPTION: Preliminary reports by several groups have demonstrated the potential for Fas ligand-based therapy to prevent transplant rejection, to treat autoimmune disease, to induce immunological tolerance and to treat cancer. The "Use of Fas Ligand to Suppress T-lymphocyte mediated Immune Responses" is protected by U.S. Patent No. 5,759,536, Donald Bellgrau and Richard C. Duke, Inventors. CERES Pharmaceuticals has licensed this Technology from the University of Colorado. The overall goal of this Phase I SBIR application is to develop and test in a well-established mouse model of arthritis, commercially-useful recombinant adenoviral gene therapy vectors encoding mutated versions of Fas ligand with enhanced therapeutic potential. These vectors and strategies for their production and application to treat human rheumatoid arthritis (U.S. Patents Pending) will be licensed to Pharmaceutical and/or Biotechnology companies for use in filing Investigational New Drug (IND) Applications with the FDA in anticipation of phase I clinical trails in humans. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
Fas ligand-dependent suppression of autoimmunity via recruitment and subsequent termination of activated T cells.
通过招募和随后终止活化的 T 细胞,Fas 配体依赖性自身免疫抑制。
DOI: 10.1016/j.clim.2004.03.011
发表时间: 2004
期刊: Clinical immunology (Orlando, Fla.)
影响因子: --
作者: [Modiano,JaimeF, Sun,Juan, Lang,Julie, Vacano,Guido, Patterson,David, Chan,Daniel, Franzusoff,Alex, Gianani,Roberto, Meech,SandraJ, Duke,Richard, Bellgrau,Donald]
通讯作者: Bellgrau,Donald
IMMUNOLOGY-IMMUNOTHERAPY
  • 批准号:
    7229225
  • 项目类别:
  • 资助金额:
    $1.24万
  • 财政年份:
    2006
  • 负责人:
    DONALD BELLGRAU
  • 依托单位:
Provoking anti-tumor immune responses with Fas ligand
  • 批准号:
    7161959
  • 项目类别:
  • 资助金额:
    $32.94万
  • 财政年份:
    2006
  • 负责人:
    DONALD BELLGRAU
  • 依托单位:
Provoking anti-tumor immune responses with Fas ligand
  • 批准号:
    7291653
  • 项目类别:
  • 资助金额:
    $33.54万
  • 财政年份:
    2006
  • 负责人:
    DONALD BELLGRAU
  • 依托单位:
IMMUNOLOGY AND IMMUNOTHERAPY
  • 批准号:
    6664437
  • 项目类别:
  • 资助金额:
    $25.04万
  • 财政年份:
    2002
  • 负责人:
    DONALD BELLGRAU
  • 依托单位: